单位:[1]Division of Trauma Surgery, Emergency Surgery & Surgical Critical, Tongji Trauma Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China外科学系急诊医学科创伤外科华中科技大学同济医学院附属同济医院[2]Department of Emergency and Critical Care Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China急诊医学科华中科技大学同济医学院附属同济医院[3]School of Laboratory Medicine, Hubei University of Chinese Medicine, Wuhan 430065, China
N6-methyladenosine (m6A) plays a role in various diseases, but it has rarely been reported in acute lung injury (ALI). The fat mass and obesity-associated (FTO) protein can regulate mRNA metabolism by removing m6A residues. This study aimed to examine the role and mechanism of the m6A demethylase FTO in lipopolysaccharide (LPS)-induced ALI. Lung epithelial FTO knockout mice and FTO knockdown/overexpression A549 cell lines were constructed to evaluate the effects of FTO on ALI. Bioinformatics analysis and a series of in vivo and in vitro assays were used to examine the mechanism of FTO regulation. Rescue assays were conducted to examine whether the impact of FTO on ALI depended on the TXNIP/NLRP3 pathway. In LPS-induced ALI, RNA m6A modification levels were upregulated, and FTO expression was downregulated. In vivo, lung epithelial FTO knockout alleviated alveolar structure disorder, tissue oedema, and pulmonary inflammation and improved the survival of ALI mice. In vitro, FTO knockdown reduced A549 cell damage and death induced by LPS, while FTO overexpression exacerbated cell damage and death. Mechanistically, bioinformatics analysis revealed that TXNIP was a downstream target of FTO. FTO deficiency mitigated pyroptosis in LPS-induced ALI via the TXNIP/NLRP3 pathway. Rescue assays confirmed that the impact of FTO on the TXNIP/NLRP3 pathway was significantly reversed by the TXNIP inhibitor SRI-37330. Deficiency of FTO alleviates LPS-induced ALI via TXNIP/NLRP3 pathway-mediated alveolar epithelial cell pyroptosis, which might be a novel therapeutic strategy for combating ALI.
基金:
The present study was supported by grants from the National Natural Science Foundation of China
(No. 82000088), Hubei Association of Pathophysiology (No. 2021HBAP002) and the Natural Science
Foundation of Hubei Province (No. 2021CFB026)
语种:
外文
PubmedID:
中科院(CAS)分区:
出版当年[2023]版:
大类|2 区医学
小类|2 区生化与分子生物学2 区细胞生物学2 区呼吸系统
最新[2025]版:
大类|2 区医学
小类|2 区生化与分子生物学2 区细胞生物学2 区呼吸系统
第一作者:
第一作者单位:[1]Division of Trauma Surgery, Emergency Surgery & Surgical Critical, Tongji Trauma Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China[2]Department of Emergency and Critical Care Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China
共同第一作者:
通讯作者:
通讯机构:[1]Division of Trauma Surgery, Emergency Surgery & Surgical Critical, Tongji Trauma Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China[2]Department of Emergency and Critical Care Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China[*1]Division of Trauma Surgery, Emergency Surgery & Surgical Critical, Tongji Trauma Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.
推荐引用方式(GB/T 7714):
Wei-Ming Xie,Wei Su,Xin-Yu Liu,et al.FTO Deficiency Alleviate LPS-induced ALI by TXNIP/NLPR3-mediated Alveolar Epithelial Cell Pyroptosis[J].American Journal Of Respiratory Cell And Molecular Biology.2024,doi:10.1165/rcmb.2023-0251OC.
APA:
Wei-Ming Xie,Wei Su,Xin-Yu Liu,Junhao Zhou,Min Wang...&Tianyu Li.(2024).FTO Deficiency Alleviate LPS-induced ALI by TXNIP/NLPR3-mediated Alveolar Epithelial Cell Pyroptosis.American Journal Of Respiratory Cell And Molecular Biology,,
MLA:
Wei-Ming Xie,et al."FTO Deficiency Alleviate LPS-induced ALI by TXNIP/NLPR3-mediated Alveolar Epithelial Cell Pyroptosis".American Journal Of Respiratory Cell And Molecular Biology .(2024)